Reported 17 days ago
Gilead Sciences raised its 2024 revenue forecast following strong third-quarter results, indicating significant growth in its legacy HIV and COVID-19 drug sales. CEO Daniel O'Day highlighted the company’s resilience compared to larger pharma firms and projected 2024 sales between $27.8 to $28.1 billion. Gilead is preparing to file for a new HIV prevention drug, lenacapavir, by year's end, further fueling investor optimism.
Source: YAHOO